search
Back to results

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Primary Purpose

Lymphoma

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
bortezomib
Sponsored by
NCIC Clinical Trials Group
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma focused on measuring Waldenstrom macroglobulinemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Diagnosis of Waldenstrom's macroglobulinemia confirmed by immunofixation or immunoelectrophoresis Newly diagnosed or untreated with IgM ≥ 20 g/L OR Previously treated with IgM ≥ 5 g/L Non-refractory, defined as no disease progression during prior therapy or within 4 weeks of the last dose of most recent prior therapy (12 weeks for rituximab) Must have 1 or more of the following: Symptomatic lymphadenopathy Hepatomegaly and/or splenomegaly Anemia (i.e., hemoglobin < 11.0 g/dL) Hyperviscosity syndrome No other lymphoproliferative disease including transformed aggressive lymphoma PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 Life expectancy At least 12 weeks Hematopoietic See Disease Characteristics Absolute granulocyte count ≥ 1,000/mm^3 Platelet count ≥ 50,000/mm^3 Hepatic Bilirubin ≤ 1.5 times upper limit of normal (ULN) AST or ALT ≤ 2.5 times ULN Renal Creatinine ≤ 1.5 times ULN Other No uncontrolled bacterial, fungal, or viral infection No pre-existing sensory or motor neurotoxicity grade 2 or greater No other prior malignancy except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor for which patient has been disease free for at least 5 years No other serious illness or medical condition that would preclude study participation No unreasonable geographical limitations Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy See Chemotherapy See Disease Characteristics At least 12 weeks since prior rituximab (for patients who have progressed) At least 24 weeks since prior rituximab (for patients who have not progressed) No prior high-dose chemotherapy and stem cell transplantation No prior radioactive monoclonal antibodies Chemotherapy See Disease Characteristics See Biologic therapy At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) No more than 2 prior chemotherapy regimens The same chemotherapy combination given for first-line and second-line therapy is considered 2 regimens Single-agent rituximab not considered 1 prior regimen No concurrent cytotoxic chemotherapy Endocrine therapy No concurrent corticosteroids Radiotherapy At least 4 weeks since prior radiotherapy (except for low-dose, non- myelosuppressive radiotherapy) and recovered No prior radiotherapy to more than 25% of bone marrow Surgery At least 4 weeks since prior major surgery Other At least 4 weeks since prior plasmapheresis At least 4 weeks since prior investigational anticancer therapy No other concurrent investigational anticancer agents or therapies

Sites / Locations

  • Hinsdale Hematology Oncology Associates
  • Abramson Cancer Center at the University of Pennsylvania
  • Tom Baker Cancer Centre - Calgary
  • Cross Cancer Institute
  • CancerCare Manitoba
  • Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre
  • Margaret and Charles Juravinski Cancer Centre
  • Cancer Care Ontario-London Regional Cancer Centre
  • Toronto Sunnybrook Regional Cancer Centre
  • Princess Margaret Hospital
  • Maisonneuve-Rosemont Hospital
  • Saskatoon Cancer Centre

Outcomes

Primary Outcome Measures

Response rate
To assess the efficacy (response rate) of PS-341 given as a bolus intravenous injection twice weekly for two out of every 3 weeks in the treatment of a population of patients with previously untreated or relapsed Waldenström's Macroglobulinemia

Secondary Outcome Measures

Toxicity
To assess the toxicity of PS-341 in patients with Waldenström's Macroglobulinemia as well as time to progression, stable disease duration and, if responses are observed, response duration.
Cytogenetics and genome profiling
To assess bone marrow and peripheral blood for cytogenetics and genome profiling by microarray in patients with Waldenstrom's macroglobulinemia.

Full Information

First Posted
September 6, 2002
Last Updated
May 16, 2013
Sponsor
NCIC Clinical Trials Group
Collaborators
National Cancer Institute (NCI), Eastern Cooperative Oncology Group
search

1. Study Identification

Unique Protocol Identification Number
NCT00045695
Brief Title
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
Official Title
A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
August 2002 (undefined)
Primary Completion Date
March 2006 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NCIC Clinical Trials Group
Collaborators
National Cancer Institute (NCI), Eastern Cooperative Oncology Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have untreated or relapsed Waldenstrom's macroglobulinemia.
Detailed Description
OBJECTIVES: Determine the efficacy of bortezomib, in terms of response rate, in patients with previously untreated or relapsed Waldenstrom's macroglobulinemia. Determine the toxicity of this drug in these patients. Determine the time to progression, stable disease duration, and response duration in patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks. Patients with complete or partial response or stable disease are followed every 3 months thereafter. PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study within 1.5-2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma
Keywords
Waldenstrom macroglobulinemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
bortezomib
Intervention Description
PS-341 bolus intravenous injection twice weekly* for 2 out of every 3 weeks
Primary Outcome Measure Information:
Title
Response rate
Description
To assess the efficacy (response rate) of PS-341 given as a bolus intravenous injection twice weekly for two out of every 3 weeks in the treatment of a population of patients with previously untreated or relapsed Waldenström's Macroglobulinemia
Time Frame
4 years
Secondary Outcome Measure Information:
Title
Toxicity
Description
To assess the toxicity of PS-341 in patients with Waldenström's Macroglobulinemia as well as time to progression, stable disease duration and, if responses are observed, response duration.
Time Frame
4 years
Title
Cytogenetics and genome profiling
Description
To assess bone marrow and peripheral blood for cytogenetics and genome profiling by microarray in patients with Waldenstrom's macroglobulinemia.
Time Frame
4 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of Waldenstrom's macroglobulinemia confirmed by immunofixation or immunoelectrophoresis Newly diagnosed or untreated with IgM ≥ 20 g/L OR Previously treated with IgM ≥ 5 g/L Non-refractory, defined as no disease progression during prior therapy or within 4 weeks of the last dose of most recent prior therapy (12 weeks for rituximab) Must have 1 or more of the following: Symptomatic lymphadenopathy Hepatomegaly and/or splenomegaly Anemia (i.e., hemoglobin < 11.0 g/dL) Hyperviscosity syndrome No other lymphoproliferative disease including transformed aggressive lymphoma PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 Life expectancy At least 12 weeks Hematopoietic See Disease Characteristics Absolute granulocyte count ≥ 1,000/mm^3 Platelet count ≥ 50,000/mm^3 Hepatic Bilirubin ≤ 1.5 times upper limit of normal (ULN) AST or ALT ≤ 2.5 times ULN Renal Creatinine ≤ 1.5 times ULN Other No uncontrolled bacterial, fungal, or viral infection No pre-existing sensory or motor neurotoxicity grade 2 or greater No other prior malignancy except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor for which patient has been disease free for at least 5 years No other serious illness or medical condition that would preclude study participation No unreasonable geographical limitations Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy See Chemotherapy See Disease Characteristics At least 12 weeks since prior rituximab (for patients who have progressed) At least 24 weeks since prior rituximab (for patients who have not progressed) No prior high-dose chemotherapy and stem cell transplantation No prior radioactive monoclonal antibodies Chemotherapy See Disease Characteristics See Biologic therapy At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) No more than 2 prior chemotherapy regimens The same chemotherapy combination given for first-line and second-line therapy is considered 2 regimens Single-agent rituximab not considered 1 prior regimen No concurrent cytotoxic chemotherapy Endocrine therapy No concurrent corticosteroids Radiotherapy At least 4 weeks since prior radiotherapy (except for low-dose, non- myelosuppressive radiotherapy) and recovered No prior radiotherapy to more than 25% of bone marrow Surgery At least 4 weeks since prior major surgery Other At least 4 weeks since prior plasmapheresis At least 4 weeks since prior investigational anticancer therapy No other concurrent investigational anticancer agents or therapies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christine I. Chen, MD
Organizational Affiliation
Princess Margaret Hospital, Canada
Official's Role
Study Chair
Facility Information:
Facility Name
Hinsdale Hematology Oncology Associates
City
Hinsdale
State/Province
Illinois
ZIP/Postal Code
60521
Country
United States
Facility Name
Abramson Cancer Center at the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104-4283
Country
United States
Facility Name
Tom Baker Cancer Centre - Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N2
Country
Canada
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Facility Name
CancerCare Manitoba
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3E 0V9
Country
Canada
Facility Name
Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1V7
Country
Canada
Facility Name
Margaret and Charles Juravinski Cancer Centre
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 5C2
Country
Canada
Facility Name
Cancer Care Ontario-London Regional Cancer Centre
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 4L6
Country
Canada
Facility Name
Toronto Sunnybrook Regional Cancer Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Facility Name
Princess Margaret Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Maisonneuve-Rosemont Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
Facility Name
Saskatoon Cancer Centre
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 4H4
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
17353550
Citation
Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Apr 20;25(12):1570-5. doi: 10.1200/JCO.2006.07.8659. Epub 2007 Mar 12.
Results Reference
result
Citation
Chen CI, White Darrell, Kouroukis TC, et al.: Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM). [Abstract] Blood 104 (11): A-3278, 2004.
Results Reference
result

Learn more about this trial

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

We'll reach out to this number within 24 hrs